PTEN activation significantly repressed downstream oncogenic pathways, and suggested that combining CRISPR activation of PTEN with conventional small molecule inhibitors, such as PI3K/mTOR or B-Raf inhibitors, could increase the efficacy of tumor inhibition and limit potential of developing resistance (215). The gene discussed is PTEN; the disease is neoplasm.